SCHEMBL2193253

SCHEMBL2193253

Cc1nc2cccc(OCc3ccccc3)n2c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.44
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MCHR1 Q99705 1/20 0.42
STAT3 P40763 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM5A P29375 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
ATP4A P20648 3/20 0.39
ATP4B P51164 3/20 0.39
BRD4 O60885 2/20 0.38
GRM5 P41594 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
SLC6A4 P31645 1/20 0.37
CYP1A2 P05177 1/20 0.37
TSHR P16473 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2193763 0.80 ATP4A (0.55) L3MBTL1MAPTMAPK1TDP1STAT3
SCHEMBL3756920 0.79 ALDH1A1 (0.40) L3MBTL1MCHR1HTTSMN1; SMN2KDM5A
SCHEMBL23016810 0.72 L3MBTL1 (0.47) L3MBTL1MAPTTDP1SMN1; SMN2KDM5A
SCHEMBL17816989 0.71 CCNB2 (0.42) L3MBTL1MAPTTDP1HTTSMN1; SMN2
SCHEMBL10921621 0.71 PI4KB (0.45) MAPTMAPK1HTTSMN1; SMN2CYP1A2
SCHEMBL18754397 0.68 HTT (0.58) MAPTMAPK1TDP1HTTSMN1; SMN2
SCHEMBL11536544 0.68 CDK8 (0.50) L3MBTL1MAPTMAPK1TDP1KDM5A
SCHEMBL1563576 0.66 GABRA5 (0.55) L3MBTL1MAPTMAPK1TDP1STAT3
SCHEMBL31002325 0.66 KDM5A (0.52) L3MBTL1MAPTMAPK1TDP1STAT3
SCHEMBL11113214 0.65 ATP4A (0.48) L3MBTL1MAPTMAPK1TDP1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150086497-A1 Skin Lightening Compositions ELC MAN LLC (US) 2015-03-26 US claimed
US-4450164-A ANTIULCER AND ANTISECRETORY AGENTS SCHERING CORPORATION (US) 1984-05-22 US claimed
EP-2521531-B1 SKIN LIGHTENING COMPOSITIONS ELC MAN LLC (US) 2017-07-12 EP disclosed
US-20170035672-A1 SKIN LIGHTENING COMPOSITIONS ELC MAN LLC (US) 2017-02-09 US disclosed
EP-3103437-A1 SKIN LIGHTENING COMPOSITIONS ELC Management LLC (US) 2016-12-14 EP disclosed
US-9314415-B2 Skin lightening compositions ELC MANAGEMENT LLC (US) 2016-04-19 US disclosed
US-8992897-B2 Skin lightening compositions ELC MANAGEMENT LLC (US) 2015-03-31 US disclosed
US-20150086497-A1 Skin Lightening Compositions ELC MAN LLC (US) 2015-03-26 US disclosed
US-20140212365-A9 SKIN LIGHTENING COMPOSITIONS NIKI YOKO (JP) 2014-07-31 US disclosed
US-20140154190-A1 Skin Lightening Compositions ELC MANAGEMENT, LLC (US) 2014-06-05 US disclosed
US-8722026-B2 Skin lightening compositions ELC MANAGEMENT, LLC (US) 2014-05-13 US disclosed
US-20140112877-A1 SKIN LIGHTENING COMPOSITIONS NIKI YOKO (JP) 2014-04-24 US disclosed
EP-2521531-A2 SKIN LIGHTENING COMPOSITIONS ELC Management LLC (US) 2012-11-14 EP disclosed
US-20110171149-A1 Skin Lightening Compositions ELC MANAGEMENT LLC 2011-07-14 US disclosed
WO-2011085015-A2 SKIN LIGHTENING COMPOSITIONS ELC MANAGEMENT LLC (US) 2011-07-14 WO disclosed
EP-0068378-B1 NOVEL IMIDAZO(1,2-A)PYRIDINES AND PYRAZINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1986-03-05 EP disclosed
US-4450164-A ANTIULCER AND ANTISECRETORY AGENTS SCHERING CORPORATION (US) 1984-05-22 US disclosed
EP-0068378-A1 Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them SCHERING CORPORATION (US) 1983-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110171149-A1 Skin Lightening Compositions CUTA, TYR, DSG1 L3MBTL1 2878/4885MAPT 114/4885MAPK1 4142/4885
US-20140212365-A9 SKIN LIGHTENING COMPOSITIONS CUTA, TYR, DSG1 L3MBTL1 2878/4885MAPT 114/4885MAPK1 4142/4885
US-20170035672-A1 SKIN LIGHTENING COMPOSITIONS CUTA, TYR, DSG1 L3MBTL1 2878/4885MAPT 114/4885MAPK1 4142/4885
US-20140154190-A1 Skin Lightening Compositions TYR, MC1R, AHR L3MBTL1 57/4885MAPT 3540/4885MAPK1 3931/4885
US-20140112877-A1 SKIN LIGHTENING COMPOSITIONS CUTA, TYR, DSG1 L3MBTL1 2878/4885MAPT 114/4885MAPK1 4142/4885
US-20150086497-A1 Skin Lightening Compositions CUTA, TYR, DSG1 L3MBTL1 2878/4885MAPT 114/4885MAPK1 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.